Symbio (4582.T) traded flat 0 % during a 24 hours period ending at 04:02 PM Central Europe on Monday 26th. One Symbio stock can currently be bought for about JPY 47 on popular exchanges. Current supply of Symbio stocks is 80.2 mn. Symbio has a current market capitalization of JPY 3.9 bn and approximately JPY 63.6 mn worth of Symbio was traded on exchanges in the last 24 hours. Since last month end, Symbio has traded -14.29 % down. Simple moving average of last 200 days is at JPY 83.3. The highest price of past 52 weeks was recorded at JPY 229 on 02/25/2026. 52 weeks low was at JPY 46 on 10/23/2026.

Here is how related stocks have performed in the past 24 hours:

  • Nihon Enterprise (4829.T) traded down -13.04 % and now trades at JPY 118. Current market capitalisation for Nihon Enterprise is JPY 4.6 bn. Current price/earnings ratio for Nihon Enterprise is 93.26.

  • Every (607A.T) traded flat 0 % and now trades at JPY 221. Every has a market capitalisation of JPY 4.6 bn.

  • Vector (2656.T) traded down -1.41 % and now trades at JPY 143. Vector has a market capitalisation of JPY 4.6 bn.

  • Plat’home (6836.T) traded down -0.82 % and now trades at JPY 952. Current market capitalisation for Plat’home is JPY 4.6 bn. Current price/earnings ratio for Plat’home is 208.39.

  • Media Kobo (3815.T) traded flat 0 % and now trades at JPY 442. Media Kobo has a market capitalisation of JPY 4.6 bn.

About Symbio

SymBio Pharmaceuticals Ltd. is a specialty biopharmaceutical company that primarily develops anti-cancer agents. The company’s main product, SyB L-0501, is a freeze-dried injected preparation that is marketed for the treatment of non-Hodgkin’s lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia under the TREAKISYM name. It is currently in the Phase III clinical trial to treat diffuse large-B-cell lymphoma. Additionally, the company is developing SyB L-1701, a ready-to-dilute preparation; SyB L-1702, a rapid infusion preparation; and SyB-C-0501, an oral preparation that is in the Phase I clinical trial for the treatment of advanced solid tumors. Preparation phase for preclinical trials is also being conducted to treat systemic lupus erythematosus. Another product in development is SyB L-1101, an intravenous formulation, which is in Phase III clinical trial for the treatment of higher-risk myelodysplastic syndromes (HR-MDS); and SyB C-1101, an oral formulation that is in Phase I/II clinical trials in combination with azacitidine to treat HR-MDS. The company primarily operates in Japan, South Korea, Taiwan, and Singapore and was founded in 2005 with its base in Tokyo, Japan.